[go: up one dir, main page]

BG102838A - Compositions containing hiv protease inhibitor such as vx 478, and water soluble vitamin b as vitamin e-trgs - Google Patents

Compositions containing hiv protease inhibitor such as vx 478, and water soluble vitamin b as vitamin e-trgs

Info

Publication number
BG102838A
BG102838A BG102838A BG10283898A BG102838A BG 102838 A BG102838 A BG 102838A BG 102838 A BG102838 A BG 102838A BG 10283898 A BG10283898 A BG 10283898A BG 102838 A BG102838 A BG 102838A
Authority
BG
Bulgaria
Prior art keywords
vitamin
trgs
water soluble
compositions containing
protease inhibitor
Prior art date
Application number
BG102838A
Other languages
Bulgarian (bg)
Other versions
BG64457B1 (en
Inventor
Arup Roy
Lloyd Tillman
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9606372.2A external-priority patent/GB9606372D0/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of BG102838A publication Critical patent/BG102838A/en
Publication of BG64457B1 publication Critical patent/BG64457B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The compositions are used in medicine. They contain HIVprotease inhibitor, in particular 38-[3R*(1R*, 2S*)]-[3-[[(4-aminophenyl)sulphonyl](2-methylpropyl)-amino]-2-hydroxy-1-phenylmethyl)propyl]carbamic acid, tetrahydro-3-furanyl ester alternatively known asVX 478 or 141 WO-94, and a tocopherol.10 claims
BG102838A 1996-03-22 1998-10-12 Hiv protease inhibitor-containing pharmaceutical form for oral administration BG64457B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1389396P 1996-03-22 1996-03-22
GBGB9606372.2A GB9606372D0 (en) 1996-03-26 1996-03-26 Pharmaceutical formulations

Publications (2)

Publication Number Publication Date
BG102838A true BG102838A (en) 1999-09-30
BG64457B1 BG64457B1 (en) 2005-03-31

Family

ID=26308992

Family Applications (1)

Application Number Title Priority Date Filing Date
BG102838A BG64457B1 (en) 1996-03-22 1998-10-12 Hiv protease inhibitor-containing pharmaceutical form for oral administration

Country Status (12)

Country Link
JP (1) JP3117726B2 (en)
AR (1) AR006345A1 (en)
BG (1) BG64457B1 (en)
CO (1) CO4790151A1 (en)
HU (1) HU228026B1 (en)
ID (1) ID16781A (en)
IL (1) IL126185A (en)
MY (1) MY126358A (en)
OA (1) OA10880A (en)
PL (1) PL187919B1 (en)
TW (1) TW455491B (en)
WO (1) WO1997035587A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2264718C (en) * 1996-09-01 2006-05-30 Pharmos Corporation Solid coprecipitates for enhanced bioavailability of lipophilic substances
AU8145198A (en) * 1997-06-16 1999-01-04 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound
US5891845A (en) * 1997-11-21 1999-04-06 Fuisz Technologies Ltd. Drug delivery systems utilizing liquid crystal structures
ES2140329B1 (en) * 1997-12-04 2000-10-16 Univ Granada USE OF MASLINIC ACID AS A PROTEASE INHIBITOR FOR THE TREATMENT OF DISEASE CAUSED BY THE VIRUSES OF ACQUIRED IMMUNODEFICIENCY.
GB9812189D0 (en) * 1998-06-05 1998-08-05 Glaxo Group Ltd Methods and compositions for increasing penetration of HIV protease inhibitors
CA2432527A1 (en) * 2000-12-22 2002-07-04 Takeda Chemical Industries, Ltd. Medicinal compositions for oral use
WO2004050068A1 (en) 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
EP1592760A4 (en) 2003-01-31 2009-08-12 Smithkline Beecham Corp Solid dispersion compositions
EP1799194B1 (en) * 2004-09-24 2011-11-16 Boehringer Ingelheim Pharmaceuticals Inc. A new class of surfactant-like materials comprising vitamin e tpgs and a water soluble polymer
EP1793806A2 (en) * 2004-09-30 2007-06-13 Eastman Chemical Company Pharmaceutical formulations containing vitamin e tpgs molecules that solubilize lipophilic drugs without significant efflux inhibition, and use of such formulations
EP1880715A1 (en) * 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
SA109300195B1 (en) 2008-03-28 2013-04-20 Astrazeneca Ab A Novel Anti-Cancer Pharmaceutical Composition
ITRM20120331A1 (en) 2012-07-12 2014-01-13 Guidotti & C Spa Labor LIQUID ORAL PEDIATRIC COMPOSITIONS CONTAINING NEPADUTANT.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016501A1 (en) * 1991-03-20 1992-10-01 Vertex Pharmaceuticals Incorporated Tetrahydroxyalkane derivatives as inhibitors of hiv aspartyl protease
NZ244986A (en) * 1991-11-08 1995-10-26 Merck & Co Inc Hiv protease inhibitor and pharmaceutical compositions
IS2334B (en) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl protease inhibitor of a new class of sulfonamides
WO1994013629A1 (en) * 1992-12-11 1994-06-23 Vertex Pharmaceuticals Incorporated Mannitol derivatives and their use as inhibitors of aspartyl protease
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
DE10199053I1 (en) * 1992-12-29 2002-08-29 Abbott Lab Retroviral protease inhibitors
ATE179164T1 (en) * 1993-01-15 1999-05-15 Agouron Pharma HIV PROTEASE INHIBITORS
WO1995012583A1 (en) * 1993-11-05 1995-05-11 Merck & Co., Inc. New quinazolines as inhibitors of hiv reverse transcriptase
IL111584A0 (en) * 1993-11-18 1995-01-24 Merck & Co Inc Prodrugs of an inhibitor of hiv protease and pharmaceutical compositions containing them
HUT74681A (en) * 1993-12-15 1997-01-28 Merck & Co Inc N-(2-hydroxy-1-indenyl)-2-phenylmethyl-4-hydroxy-5-(2-carboxamido-piperazinyl)-pentaneamide derivatives of hiv protease inhibitor activity and phrmaceutical compositions contining them
WO1995024385A1 (en) * 1994-03-07 1995-09-14 Vertex Pharmaceuticals Incorporated Sulphonamide derivatives as aspartyl protease inhibitors
GB9409778D0 (en) * 1994-05-16 1994-07-06 Dumex Ltd As Compositions
US5527829A (en) * 1994-05-23 1996-06-18 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
EP0825849A1 (en) * 1995-05-19 1998-03-04 Abbott Laboratories Self-emulsifying formulations of lipophilic drugs

Also Published As

Publication number Publication date
ID16781A (en) 1997-11-13
JP3117726B2 (en) 2000-12-18
IL126185A0 (en) 1999-05-09
MY126358A (en) 2006-09-29
IL126185A (en) 2003-05-29
TW455491B (en) 2001-09-21
PL187919B1 (en) 2004-11-30
PL328916A1 (en) 1999-03-01
OA10880A (en) 2001-10-11
WO1997035587A1 (en) 1997-10-02
HUP9901887A2 (en) 1999-12-28
AR006345A1 (en) 1999-08-25
BG64457B1 (en) 2005-03-31
JP2000500504A (en) 2000-01-18
HU228026B1 (en) 2012-08-28
HUP9901887A3 (en) 2000-02-28
CO4790151A1 (en) 1999-05-31

Similar Documents

Publication Publication Date Title
BG102838A (en) Compositions containing hiv protease inhibitor such as vx 478, and water soluble vitamin b as vitamin e-trgs
FR2762512B1 (en) LUPINE OIL COMPOSITIONS, ESPECIALLY BASED ON LUPINE OIL AND WHEAT GERM OIL AND THEIR USE IN COSMETOLOGY, PHARMACY AND AS A FOOD SUPPLEMENT
MY112093A (en) Cosmetic delivery system for salicylic acid and process for preparation of the same.
AU6628496A (en) Polyether block copolymer micellar compositions for targeting biological agents
MX9605359A (en) COMPOSITIONS FOR THE CLEANING OF FABRICS CONTAINING BPN SUBTILICINE VARIANTS.
AU6985691A (en) Pharmaceutical and cosmetic compositions
ID28003A (en) ADAMANTANA'S DEMONS
ATE204297T1 (en) PEPTIDE ANALOGUES OF LH-RH, THEIR USES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FI953442A0 (en) Freeze-dried beads containing gonadotropin
EP1074243A3 (en) Cosmetic compositions
CA2191112A1 (en) Gel Stick Compositions Comprising Optically Enriched Gellants
CA2142998A1 (en) N-(alkanoylamino-2-hydroxypropyl)-sulfonamides useful as retroviral protease inhibitors
HUP9801562A3 (en) Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
TR199501316A2 (en) Compressed mixed air-pump.
ES1034280U (en) Counter for parlour games
AU1306997A (en) Pharmaceutical compositions with vitamin d analogues
CA2405097A1 (en) Coloured ophthalmic product
CA2433285A1 (en) Blood lipid ameliorating composition
IL110724A0 (en) Retroviral protease inhibitors, their preparation and pharmaceutical compositions containing them
ATE305517T1 (en) NEUROTRYPSIN
CA2386423A1 (en) Pharmaceutical compositions containing copper, salicylic acid and vitamines c
BR9802803A (en) action and pharmaceutical compositions containing them.
DE69521315D1 (en) HIRUDINE CONTAINING PHARMACEUTICAL COMPOSITIONS
CA2249336A1 (en) Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs
EP1011329A4 (en) 7-methylthiooxomethyl and 7-methylthiodioxomethyl paclitaxels